Registration, quality assurance and the shape of a medicines contract
A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programs -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.
Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.
The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and program funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.
This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.
Who buys pharmaceuticals in Norway?
GlobalGov holds 591 pharmaceuticals records from 111 distinct buying organizations in Norway. The most frequent publishers are Sykehusinnkjøp HF (148 records); Arbeids- Og Velferdsetaten (48 records); Sykehusinnkjøp HF (26 records); EU Agency (13 records); Oslo kommune v/ Vann- og avløpsetaten (8 records); Forsvaret v/Forsvarets logistikkorganisasjon (7 records). Between them the 6 largest account for 42% of everything published, so buying here is spread across many separate authorities.
| Buying organization | Records | Share |
|---|---|---|
| Sykehusinnkjøp HF | 148 | 25% |
| Arbeids- Og Velferdsetaten | 48 | 8.1% |
| Sykehusinnkjøp HF | 26 | 4.4% |
| EU Agency | 13 | 2.2% |
| Oslo kommune v/ Vann- og avløpsetaten | 8 | 1.4% |
| Forsvaret v/Forsvarets logistikkorganisasjon | 7 | 1.2% |
What are pharmaceuticals contracts worth in Norway?
368 of the 591 records publish a contract value. The median is $12.8M and the largest single published value is $6.8B. By size, 1 under $100k, 83 between $100k and $1M, 140 between $1M and $10M, 144 above $10M. The remaining 223 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.
| Contract size | Records | Share of priced |
|---|---|---|
| under $100k | 1 | 0.3% |
| between $100k and $1M | 83 | 23% |
| between $1M and $10M | 140 | 38% |
| above $10M | 144 | 39% |
How long do bidders get to respond to pharmaceuticals tenders in Norway?
Across the 145 Norway pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 34 days. A quarter of them allowed 28 days or fewer and a quarter stayed open for more than 39. Short turnarounds are the exception rather than the rule here: only 6 (4.1%) closed within a fortnight of being published.
How often are pharmaceuticals tenders published in Norway?
Norway publishes about 12 notices a month in this category, 146 in the last twelve months. That is 170% more than the 54 published in the twelve months before that. Over the last three years there were 253, spread across 89 separate months of activity since 30 September 2003. October is historically the busiest month. The most recent was published 18 November 2026.
How does Norway compare with other pharmaceuticals markets?
Among the 45 countries where GlobalGov holds a comparable pharmaceuticals market, Norway ranks 16th by number of records. The largest is Poland (9,417 records against 591 here). Within Norway itself, pharmaceuticals is the 19th largest of the 70 procurement categories tracked here.
Where do the Norway pharmaceuticals records on this page come from?
These 591 records are collected from 2 official sources: TED (478), Doffin (113). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-11-22.
Open Pharmaceuticals tenders in Norway
Showing 4 of the 11 notices open in this category today. Openness uses the same definition as the Norway market page: active, not marked awarded, cancelled, closed or expired, and either closing in the future or published within the last 90 days with no stated closing date.
Norway – Medical equipments, pharmaceuticals and personal care products – 2661a RHF seasonal flu vaccine
Norway – Medical equipments, pharmaceuticals and personal care products – Market dialogue: Procurement of electronic medicine cabinets and medicine trolleys for Drammen municipality.
Norway – Health and social work services – Invitation to a supplier conference for a coming procurement of multi-disciplinary specialised drug treatment (TSB)
Other procurement categories in Norway
Pharmaceuticals procurement in other markets
Never Miss a Norway Government Contract
Finding Norway tenders usually means a local portal, a local registration and someone who reads the language. Get an alert you can read when a new pharmaceuticals opportunity is published there.
Start Free Trial